

For personal use only

## 1H FY24 RESULTS

Dr. Ian Kadish  
Managing Director & CEO

Craig White  
CFO

20 February 2024




# IDX VISION, PURPOSE AND VALUES

Vision: A Healthier World

Purpose: Deliver The Best Health Outcome For Every Patient We Serve

For personal use only



# DELIVERING ON OUR VALUES – 1H FY24

For personal use only



## patients first

PATIENTS ARE AT THE HEART OF EVERYTHING WE DO

- Served >600,000 patients
- Performed 1.3 million exams
- Invested \$11.7m in capex, including investment in additional or upgraded equipment
- Continued to adopt technology to enhance the patient and referrer experience



## medical leadership

IMPROVING OUTCOMES WITH EVIDENCE BASED CARE

- 254 reporting radiologists
  - ✓ 163 employees
  - ✓ 91 contractors
  - ✓ 107 radiologist shareholders
- Delivering leadership programs for Radiologists
- Continued growing IDXt, IDX's teleradiology reporting platform, to provide services to more external clients
- Ongoing development of sub-specialty reporting to capitalise on our specialist expertise, assisted by AI enhanced screening and detection



## everyone counts

WE WORK SAFELY, INCLUSIVELY AND RESPECT EACH OTHER

- 1,968 employees
- Conducted “temp-check” and “pulse” surveys demonstrating continued improvement in engagement scores
- Ongoing promotion of organisation-wide Employee Recognition Program
- Continued focus on delivering our ESG strategy in accordance with regulatory requirements



## create value

DELIVER SUSTAINABLE VALUE TO ALL STAKEHOLDERS

- Increased revenue by 7.2% to \$231.3m
- Increased Operating EBITDA by 8.7% to \$43.2m
- Operating NPAT declined by 5.6% to \$7.4m due to prolonged cost inflation and higher interest rates
- Declared 1H FY24 fully franked interim dividend of 2.5cps
- Invested \$3.5m in growth initiatives
- 5,605 IDX shareholders at 31 December 2023



## embrace change

STRIVE FOR EXCELLENCE, HAVE THE COURAGE TO INNOVATE

- Undertook restructure in light of prolonged cost inflation to position the business well for future growth
- Broadened referrer base in NZ to combat non-arms length referral practices

# 1H FY24 FINANCIAL HIGHLIGHTS

Solid revenue growth of 7.2% offset by prolonged cost inflation to deliver Operating EBITDA growth of 8.7% and a slightly higher Operating EBITDA margin of 18.7% vs prior corresponding period of 18.5%


Statutory NPAT (\$66.8m)	5.6% decrease in operating NPAT \$7.4m	8.7% increase in operating EBITDA \$43.2m	6.4% decrease in operating diluted EPS 3.1cps	7.2% increase in revenue \$231.3m	41.3% decrease in free cash flow \$24.0m	Net debt / EBITDA (pre-AASB 16) 3.0x
-----------------------------	---	--	--	--------------------------------------	---	---

IDX's operating results for 1H FY24 are consistent with the Trading Update provided on 3 November 2023:

- Solid revenue growth of 7.2% driven by improved Medicare indexation (3.6% increase effective 1 July 2023 and an additional 0.5% increase effective 1 November 2023, both increases exclude nuclear medicine), annualisation of FY23 out of pocket fee increases and continued favourable mix impact
- Prolonged cost pressures, especially higher labour costs, driven by inflation and labour market supply constraints, together with higher interest funding costs. Management has focused on containing and reducing costs wherever possible
- Operating EBITDA margin of 18.7%, being an increase of 20 bps compared to 18.5% in the prior corresponding period
- An impairment loss of \$71.5m recognised in the New Zealand division, being 35.1% of the \$203.5m carrying value of IDX's New Zealand assets, reflecting the Company's revised, more modest growth expectations for this business, consistent with the Trading Update provided on 3 November 2023
- Statutory Loss after Tax of (\$66.8m) after impairment losses, transaction and integration costs, amortisation of customer contracts and other costs, net of tax, of \$74.2m
- Free cash flow conversion impacted by timing of working capital movements in 1H FY24
- Net debt to EBITDA (pre-AASB 16) of 3.0x at 31 December 2023, being slightly below 3.1x at 31 December 2022, and projected to trend down gradually over time.

# DI INDUSTRY REFLECTING COVID-19 IMPACT: AUSTRALIA

Industry growth rates, on a 12-month rolling basis, reflect improvement in CY23. Prior to this, after coming back strongly in CY21, industry growth rates declined significantly in CY22 given the onset of the Omicron variant of COVID-19, as well as influenza, together with the lingering impact of these events





Source: Medicare Australia Statistics by 'Broad Type of Service' (BTOS), for the States in which IDX operates. Published industry data is not available for the New Zealand market.

# SHAREHOLDER RETURNS

Fully franked interim dividend of 2.5cps (1H FY23: 2.5cps), representing 78.9% of 1H FY24 Operating NPAT

For personal use only



The 1H FY24 dividend record date is 1 March 2024 with a payment date on 2 April 2024. The Dividend Reinvestment Plan (DRP) is available for participation for the 1H FY24 dividend at a 1.5% discount.

For personal use only

# FINANCIAL PERFORMANCE

1H FY24 Results



## RESULTS FOR 1H FY24

AUD \$m	1H FY24	1H FY23	Var. (\$)	Var. (%)
Revenue	231.3	215.7	15.6	7.2%
Operating EBITDA <sup>(1)</sup>	43.2	39.8	3.4	8.7%
Operating EBITDA margin	18.7%	18.5%		
Operating EBITA <sup>(1)</sup>	21.2	19.6	1.6	7.9%
Operating EBITA margin	9.2%	9.1%		
Operating NPAT <sup>(1)</sup>	7.4	7.8	(0.4)	(5.6%)
Operating Diluted EPS (cps)	3.1	3.3	(0.2)	(6.1%)
Free cash flow	24.0	40.9	(16.9)	(41.3%)
Free cash flow conversion, prior to replacement capital expenditure	74.6%	124.3%		
<b>As at:</b>	<b>31 Dec 2023</b>	<b>31 Dec 2022</b>		
Net debt (pre-AASB 16) <sup>(2)</sup>	210.0	194.2		
Net debt / pro forma EBITDA (pre-AASB 16) <sup>(2)(3)</sup>	3.0x	3.1x		
Equity	300.4	370.5	(70.1)	

- 1) Non-operating transactions not included in operating metrics include the impact of impairment losses, remeasurement of contingent consideration liabilities, transaction and integration costs, share based expenses for radiologists, amortisation of customer contracts, adjustments to non-operating provisions, and one-off systems implementation costs, net of tax of \$74.2m (1H FY23: \$8.3m). Refer to slide 24 for further detail.
- 2) The impact of AASB 16: Leases on 1H FY24 results was an increment to Operating EBITDA of \$10.1m, an increment to Operating EBITA of \$1.7m and a decrement to Operating NPAT of (\$0.8m), using the approximate cash cost of these ongoing leases in making these adjustments. The impact of AASB 16: Leases on 1H FY23 results was an increment to Operating EBITDA of \$9.5m, a decrement to Operating EBITA of \$1.6m and a decrement to Operating NPAT of (\$0.7m), using the approximate cash cost of these ongoing leases in making these adjustments.
- 3) 1H FY24 net debt/pro forma EBITDA ratio is based on net debt at 31 December 2023 of \$210.0m and LTM organic EBITDA (plus trailing acquisitions EBITDA) of \$69.4m. 1H FY23 is based on net debt at 31 December 2022 of \$194.2m and LTM organic EBITDA (plus trailing EBITDA from acquisitions) of \$63.5m.

# REVENUE

Solid revenue growth of 7.2% to \$231.3m

- Solid revenue growth of 7.2% driven by improved Medicare indexation (3.6% increase effective 1 July 2023 and an additional 0.5% increase effective 1 November 2023, both increases excluding nuclear medicine), annualisation of FY23 out of pocket fee increases and continued overall favourable mix impact
- Organic operating revenue from all sources (including reporting contracts, some of which are fixed rate) in Australia grew 7.8%, being slightly lower compared to the Medicare industry weighted average for the States in which IDX operates of a 9.5% benefits increase adjusted for working days. Note that IDX's growth is off a higher base relative to the industry weighted average for the States in which IDX operates given the more regional nature of IDX's operations which were less impacted by COVID-19 in the prior corresponding period.
- Average fees per exam (including reporting contracts) in Australia increased by 7.5% in 1H FY24, reflective of Medicare indexation, annualization of FY23 out of pocket fee increases and an on-going move to the higher end CT, MRI and PET scan modalities as noted above.
- Organic operating revenue in New Zealand grew 4.1%, on a constant currency basis adjusted for working days.

All revenue presented above is denominated in Australian dollars (\$AUD).



For personal use only



## OPERATING EXPENDITURE

Operating expenses decreased by 20 basis points as a percentage of revenue, despite labour costs increasing by 20 basis points as a % of revenue driven by inflation and labour market supply constraints

AUD \$m	1H FY24	1H FY23	Var. (\$)	Var. (%)	% of Group Revenue	
					1H FY24	1H FY23
Consumables	11.4	10.7	0.7	6.7%	4.9%	4.9%
Labour	145.4	135.2	10.2	7.6%	62.9%	62.7%
Equipment	7.6	7.8	(0.2)	(1.9%)	3.3%	3.6%
Occupancy	5.4	4.1	1.3	31.9%	2.3%	1.9%
Other expenses	18.2	18.0	0.2	1.2%	7.9%	8.4%
Operating expenses	188.0	175.8	12.2	7.0%	81.3%	81.5%

- Consumables were consistent with the prior comparative period, when expressed as a percentage of revenue.
- Labour costs increased by 20 basis points as a percentage of revenue driven by inflation and radiologist demand vs supply cost pressures present in the industry.
- Equipment costs decreased 30 basis points as a percentage of revenue, reflecting the timing of warranty periods and maintenance profile of capital equipment.
- Occupancy costs increased by 40 basis points as a percentage of revenue due to the inflationary impact of CPI increases, utilities costs and adjustments to the makegood provision in 1H FY23.
- Other costs decreased by 50 basis points as a percentage of revenue, reflecting a continued focus on discretionary cost discipline and some fixed cost leverage.

# CAPITAL MANAGEMENT

## Solid balance sheet

- 1H FY24 net debt of \$210.0m<sup>(1)</sup> (1H FY23: \$194.2m), being 3.0x<sup>(2)</sup> EBITDA prior to non-operating transactions at 31 December 2023 (1H FY23: 3.1x<sup>(2)</sup>) on a pre-AASB 16 basis.
- Significant liquidity headroom of \$126.3m<sup>(1)</sup> available under Group debt facilities (subject to banking facility financial covenant compliance).
- Cash and cash equivalents have decreased by \$15.9m, reflecting timing of payments to suppliers, contingent consideration payments and higher interest payments.
- Other current assets increased by \$5.0m from June 2023 due to the timing of prepayments (insurance, equipment service and software licensing contracts) and accrued revenue.
- The increase in the current tax receivable reflects the expected \$10.4m FY23 tax refund position for the Australian entities, as well as provisional tax installments paid on FY24 earnings.
- The decrease in intangible assets reflects the impairment loss recorded against the New Zealand operations in the current period.
- All other assets and liabilities have moved in line with the operating performance of the Group in the current period.
- Net assets decreased \$72.6m or 19.5% compared to 30 June 2023.

AUD \$m	31 Dec 2023	30 Jun 2023
Cash and cash equivalents	18.0	33.9
Trade and other receivables	22.4	21.7
Other current assets	12.1	7.1
Current tax receivable	13.2	0.1
<b>Total current assets</b>	<b>65.7</b>	<b>62.7</b>
Property, plant and equipment	151.2	153.1
Right of use assets	124.8	129.4
Intangible assets	404.1	474.8
Investments accounted for using the equity method	0.0	0.0
Deferred tax assets	-	3.8
<b>Total non-current assets</b>	<b>680.1</b>	<b>761.0</b>
<b>Total assets</b>	<b>745.8</b>	<b>823.8</b>
Trade and other payables	28.3	31.1
Contingent consideration	10.9	7.5
Borrowings	3.3	2.5
Lease liabilities	14.6	14.2
Provisions	29.0	27.4
<b>Total current liabilities</b>	<b>86.1</b>	<b>82.7</b>
Borrowings	220.5	221.1
Lease liabilities	123.1	127.3
Contingent consideration	0.4	7.8
Deferred tax liabilities	6.6	2.4
Provisions	8.8	9.5
<b>Total non-current liabilities</b>	<b>359.4</b>	<b>368.1</b>
<b>Total liabilities</b>	<b>445.4</b>	<b>450.7</b>
<b>Net assets</b>	<b>300.4</b>	<b>373.0</b>

(1) Including asset financing (\$50.9m) and guarantee facilities (\$3.2m)


(2) Based on net debt at 31 December 2023 of \$210.0m and LTM organic EBITDA (plus trailing acquisitions EBITDA) of \$69.4m. 1H FY23 is based on net debt at 31 December 2022 of \$194.2m and LTM organic EBITDA (plus trailing EBITDA from acquisitions) of \$63.5m.

## CASH FLOW AND CASH CONVERSION

Free cash flow conversion impacted by timing of working capital movements in 1H FY24

AUD \$m	1H FY24	1H FY23	Var. (\$)	Var. (%)
Operating EBITDA	43.2	39.8	3.4	8.7%
Non-cash items in EBITDA	0.9	(0.2)	1.1	(578.8%)
Changes in working capital	(4.4)	16.9	(21.3)	(125.9%)
Cash payments on leases	(7.5)	(7.1)	(0.4)	6.3%
Replacement capital expenditure	(8.2)	(8.5)	0.3	(3.7%)
Free cash flow	24.0	40.9	(16.9)	(41.3%)
Growth capital expenditure	(3.5)	(5.1)	1.6	(31.8%)
Net cash flow before financing, acquisitions and taxation	20.5	35.8	(15.3)	(42.7%)
Free cash flow conversion, prior to replacement capital expenditure	74.6%	124.3%		

- Free cash flow conversion, prior to replacement capital expenditure of 74.6% (1H FY23: 124.3%)
- Changes in working capital includes the recognition of a \$10.4m tax receivable, expected to be received in 3Q FY24. Adjusting for this tax receivable would increase free cash flow conversion to 98.6%
- Working capital in the prior comparative period excludes accruals for non-operating transaction costs and capex as well as working capital acquired on 1 July 2022 as part of the Peloton Radiology and Horizon Radiology acquisitions
- Growth capital expenditure was \$3.5m in 1H FY24



# CAPITAL EXPENDITURE

Capex investment aligned with IDX's strategy

## 1H FY24 Replacement capex of \$8.2m

Replacement capex reflects capital sensitivity requirements, site refurbishments and other end of life equipment replacements. 1H FY24 has seen replacement or upgrade of 4 CT machines, 18 Ultrasound machines, 1 MRI machine, 2 mammography machines, 4 X-ray machines and IT upgrades.

## 1H FY24 Growth capex of \$3.5m

Project spend for 1H FY24 included:

### Australia

- Various minor works (\$0.6m), with growth capex skewed to 2H FY24

### New Zealand

- PET building works for Cavendish site (\$1.3m)

### Information Technology

- Implementation of integrated Radiology Information System (RIS) for New Zealand businesses (\$0.9m)
- Server and network upgrades to support business growth (\$0.7m)



For personal use only

For personal use only

# REGULATORY UPDATE

1H FY24 Results



# REGULATORY ENVIRONMENT

## Australia:

### MRI Licences

- On 1 November 2022, the Federal government de-regulated MRI services in regional and rural areas, defined as Modified Monash Model 2-7. As at the date of this presentation no further licences or plans for deregulation of MRI licences have been announced for MM1 areas.

### Medicare Changes

- Indexation of 3.6% announced and applied to all Diagnostic Imaging Services, including MRI items however excluding Nuclear Medicine items, from 1 July 2023, with further indexation of 0.5% applied from 1 November 2023.
- Bulk billing incentive on MRI reduced to 95% of CMBS from 100% from 1 July 2022. This only affects MRI services currently bulk billed to Medicare.
- On 1 November 2023, Medicare trebled the bulk billing incentive for GP's (represents a meaningful uplift for regional GP's).

## New Zealand:

- There is limited indexation of pricing in New Zealand, however we have received CPI like increases commencing in December 2023 from the majority of private health insurers and continue to negotiate with other funders.
- The regulatory authorities in New Zealand have determined that non-arms length referral practices by referrers who own interests in radiology practices or equipment are acceptable. IDX is pursuing various strategic initiatives as a result of this situation, including developing its referrer base in the New Zealand general practitioner market, a market segment that is less impacted by non-arms length referrals.

## Australia and New Zealand:

- International medical graduates (radiologists and referring doctors) and other clinicians (including sonographers and nucmed technologists) are slowly returning to New Zealand and regional Australia, helping to alleviate the skills shortage.

For personal use only

# STRATEGY UPDATE & OUTLOOK

1H FY24 Results



# MANAGEMENT'S STRATEGY – GOOD MEDICINE IS GOOD BUSINESS

For personal use only



The Company believes the fundamentals of the essential radiology industry are strong. Our industry benefits from being at the confluence of major global trends – demographic and technological:

- Demographically, the ageing of the population and the increased prevalence of chronic disease and earlier detection will drive demand for diagnostic services
- Technological advancements, digitisation and the growth of teleradiology and AI is expected to improve the quality and efficiency of the care we deliver
- Structural shifts to higher acuity modalities

IDX as a **specialist, regionally focused, high quality provider** of diagnostic services is strategically well positioned to benefit from these important trends and to grow services strongly going forward.

In FY24 and beyond the Company is focused on executing on the above mentioned drivers of IDX's strategy to grow it's business.

In particular, the focus on execution of key operational improvement initiatives are expected to lead to an improvement in 2H FY24 trading performance and Operating EBITDA margin compared to 1H FY24, to be in line with or slightly higher than the 2H FY23 EBITDA margin of 20.2%.

For the month of January 2024 and up to and including 15 February 2024, the Company achieved solid revenue growth of 11.6% (7.8% adjusted for working days) compared to the prior corresponding period.

FY24 replacement and growth capex is expected to be between \$30.0m to \$40.0m.



# OUR FOCUS IS ON EXECUTION OF KEY OPERATIONAL IMPROVEMENT INITIATIVES



## Improve Patient & Referrer Experience

- Continued roll out of integrated patient booking system to minimise patient wait times and patient waiting lists
- Strengthen referrer relationships through priority service lines and enhanced e-referral platforms
- Educate patients and referrers on selected radiology tests for early diagnosis eg high resolution Chest CT for all smokers and Cardiac CT's for patients at risk of heart disease



## Workforce Development

- Enhance clinical productivity, including sub-specialty reporting, through use of technology, such as integrated worklists and AI
- Grow Sonographer training program to address workforce shortages
- More closely align staffing levels to match patient demand
- Increased regional radiologist registrar training positions at IDX sites



## Increase Productivity & Efficiency

- Simplify and reduce management layers in organization structures so that decisions can be made closer to the frontline
- Continue to drive non-labour cost efficiencies
- Grow tele-radiology service to assist in cost-effectively balancing the workload



## Lift Asset Utilisation

- Focus on improving utilisation of existing installed machine base
- Selected investment in higher end modalities within FY24 budgeted growth capex
- Targeting more capital light teleradiology tenders eg secured our first NSW teleradiology tender


# SAVING LIVES THROUGH TELERADIOLOGY AND ARTIFICIAL INTELLIGENCE (AI)

## IDX Teleradiology (IDXt)

- Launched in August 2020, provides services internally to the IDX group, and externally to public hospitals and private radiology practices
- Grown rapidly organically - now includes 65 contracted radiologists, and reports ~15% of IDX Australian revenue
- Facilitates sub-specialist reporting for advanced specialist care
- Allows radiologists in different time zones to provide overnight reporting during daytime hours
- Provides flexibility for radiologists to report at the time and place they select
- Variable reimbursement model based on individual output
- IDXt serves State hospitals in WA, QLD and VIC, and recently secured our first NSW public tender

## AI in IDX

- Commenced at Apex Radiology in February 2019, in IDXt in 2020, now utilized in most IDX business units
- Shortens time for recognition of AI detected cases, allowing for improved patient outcomes
- Includes important CT-based algorithms for the detection of intracranial haemorrhage; brain aneurysm; large vessel occlusion; acute and incidental pulmonary embolism; cervical spine fracture; rib fracture; and 'Bone View' which is our first general X-ray algorithm for bone fractures
- Currently accounts for >5% of IDX volumes and growing
- IDX is a luminary site for AIDOC (a leading international radiology AI supplier)



# ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)

For personal use only

IDX continues to implement and develop its ESG strategy aligned to its values and with a view to complying with the proposed climate-related disclosure standards in Australia.

Details of our ESG activities have been published in our FY23 ESG report



## Our Values

## Our Strategies

## SDGs aligned with strategy FY22-FY26



**patients first**  
PATIENTS ARE AT THE HEART OF EVERYTHING WE DO

- Improving access to radiology services
- Climate action



**medical leadership**  
IMPROVING OUTCOMES WITH EVIDENCE BASED CARE

- Driving public health outcomes
- Advocacy



**everyone counts**  
WE WORK SAFELY, INCLUSIVELY AND RESPECT EACH OTHER

- Diversity and inclusion
- Employee engagement, development and wellbeing



**create value**  
DELIVER SUSTAINABLE VALUE TO ALL STAKEHOLDERS

- Engaging with the local community
- Environment and ethical supply chain



**embrace change**  
STRIVE FOR EXCELLENCE, HAVE THE COURAGE TO INNOVATE

- Driving technology and innovation
- Resource efficiency



For personal use only

# QUESTIONS

1H FY24 Results



For personal use only

# APPENDICES

1H FY24 Results



# IDX TODAY - GROUP OVERVIEW - DECEMBER 2023

For personal use only

	Victoria		Queensland			Western Australia	New Zealand	
							   	
Geographic Market	Victoria	Victoria & NSW	Queensland	Queensland & NSW	Queensland	Western Australia	New Zealand	
Core markets	Ballarat, Geelong, Warrnambool and outer western areas of Melbourne	Albury, Wodonga, Wangaratta, Yarrawonga and Lavington	Sunshine Coast, Rockhampton and Gladstone	Gold Coast, Toowoomba and Mackay	Brisbane, Sunshine Coast	South West, Western Australia	Auckland	Total IDX
Sites	17	5	16	17	9	6	20	90
Comprehensive sites <sup>1</sup>	6	2	7	8	3	4	5	35
MRI machines	8	2	6	9	3	3	6	37
MRI Licences <sup>6</sup>	4 full 0 partial	1 full 0 partial	3 full 2 partial	5 full 2 partial	0 full 3 partial	2 full 0 partial	N/A	15 full 7 partial
PET Scanners	2	-	-	2	-	1	1	6
Employed Radiologists <sup>2</sup>	47	4	25	37	6	10	34 <sup>3</sup>	163
# of Employees	386	68	330	431	171	197	226	1,809 <sup>4</sup>

These tables reflect data current at 31 December 2023.

1. Comprehensive sites include a range of radiology equipment including MRI's and CT's and are located with or near major specialist referrers.
2. Relates to employed radiologists only. In addition, IDX has had 91 contractor radiologists providing services.

3. Consistent with the NZ private radiology model, all doctors work across the public and private sector and meet the criteria to be classified as contractors but are on terms and conditions similar to IDX employed radiologists.
4. This number represents the number of employees on employment contracts on either part time or full time arrangements. It does not represent the number of full time

equivalent employees or individual casual/contract arrangements. In addition there are 159 employees in the corporate office (including IDXt) totalling 1,968 employees.



## RECONCILIATION OF OPERATING TO REPORTED EBITDA AND STATUTORY NPAT

AUD \$m	1H FY24	1H FY23	Change (\$)	Change (%)
Operating NPAT	7.4	7.8	(0.4)	(5.6%)
<i>Non operating transactions net of tax</i>				
Remeasurement of contingent consideration liabilities	-	14.1		
Transaction and integration benefits/(costs)	(0.9)	(3.6)		
Restructuring activities	(0.6)	-		
Share based expenses	(0.5)	(1.0)		
Share of net profit of joint ventures	(0.1)	(0.2)		
Amortisation of customer contracts	(0.6)	(0.9)		
Impairment loss on New Zealand operations	(71.5)	-		
Statutory NPAT	(66.8)	16.1	(82.9)	(513.7%)
AUD \$m	1H FY24	1H FY23	Change (\$)	Change (%)
Operating EBITDA	43.2	39.8	3.4	8.7%
<i>Non operating transactions</i>				
Remeasurement of contingent consideration liabilities	-	14.1		
Transaction and integration costs	(2.2)	(4.4)		
Restructuring activities	(0.9)	-		
Share based expenses	(0.5)	(1.0)		
Share of net profit of joint ventures	(0.1)	(0.2)		
Impairment loss on New Zealand operations	(71.5)	-		
Reported EBITDA	(31.9)	48.2	(80.1)	(166.2%)

1) 1H FY24 transaction and integration costs consist of \$1.1m relating to acquisitions and integration activities, and \$1.1m of one-off systems implementation costs, on a pre-tax basis.

2) 1H FY24 non-operating share-based expenses primarily relate to the loan funded share/option plan for radiologists.

3) 1H FY24 amortisation of customer contracts relates to the acquisition of Imaging Queensland (\$0.3m), Astra Radiology (\$0.1m), Horizon Radiology (\$0.3m) and the X-Ray Group (\$0.1m) on a pre-tax basis.

## SUPPLEMENTARY INFORMATION – ITEMS BELOW EBITDA

AUD \$m

1H FY24 Comments

### *Operating costs below EBITDA (excluding tax)*

Depreciation of property, plant & equipment	13.6	Depreciation charge on PP&E and capitalised software
Depreciation of right of use assets	8.4	Formerly treated as lease expense prior to the introduction of AASB 16
<b>Total Depreciation</b>	<b>22.0</b>	
Finance income	(0.4)	Interest income earned on cash held
Finance cost - debt facilities	8.6	Interest costs incurred on debt facilities
Finance cost - right of use assets	2.8	Formerly treated as lease expense prior to the introduction of AASB 16
Finance cost - other	(0.0)	Costs associated with discounting non-current liabilities and FX
<b>Total interest cost (net)</b>	<b>11.0</b>	
<b>Total operating costs below EBITDA (excluding tax)</b>	<b>33.0</b>	

### *Non-operating costs below EBITDA (excluding tax)*

Amortisation of customer contract intangibles	0.8	Amortisation of intangible assets recognised through business combinations
<b>Total non-operating costs below EBITDA (excluding tax)</b>	<b>0.8</b>	
<b>Total costs below EBITDA (excluding tax)</b>	<b>33.8</b>	

For personal use only

## DISCLAIMER

1. Some of the information contained in this presentation contains “forward-looking statements” which may not directly or exclusively relate to historical facts. These forward-looking statements reflect Integral Diagnostics Limited (IDX) current intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors, many of which are outside the control of IDX.
2. Important factors that could cause actual results to differ materially from the expectations expressed or implied in the forward-looking statements include known and unknown risks. Because actual results could differ materially from IDX current intentions, plans, expectations, assumptions and beliefs about the future, you are urged to view all forward-looking statements contained herein with caution.
3. Past performance of IDX cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of IDX.
4. To the maximum extent permitted by law, none of IDX, or its respective affiliates or related bodies corporate or any of their respective officers, directors, employees and agents (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, IDX, the Group or IDX securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.
5. Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not a financial product or investment advice or recommendation to acquire IDX securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in IDX and should not rely on this presentation. In all cases, you should conduct your own research of IDX and the Group and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of IDX, the Group and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

For personal use only

**THANK YOU**

1H FY24 Results

